OrbiMed Sells $39 Million Worth of Enliven Therapeutics Shares Amid Significant Stock Rally
On June 22, 2026, OrbiMed Advisors sold approximately 860,123 shares in Enliven Therapeutics (NASDAQ:ELVN) for around $39 million. The transaction marked a reduction of about 11.6% of its indirect holdings but did not represent a full exit from the company. Enliven's stock has surged by 130% over the past year, closing at $45.96 on June 22 and reaching $50 as of June 26.
Tickers: $ELVN
Topics: Enliven Therapeutics OrbiMed Advisors SEC Form 4 stock sale